L-tyrosine Mood Randomized Trial: What the Evidence Says

Quick Answer

L-tyrosine Mood Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• As a result of rising living standards, dietary and lifestyle modifications, and the increasing incidence of psychological disorders, the prevalence of NAFLD has sharply increased in recent years. [Milkarizi Narges (2026); evidence level 2]
• In addition, NAFLD is associated with a higher incidence of psychological disorders, such as anxiety and depression. [Milkarizi Narges (2026); evidence level 2]
• Increasing evidence suggests that no single biomarker is likely to capture this complexity, and that integrative multi-omics approaches may provide a more clinically meaningful framework for precision psychiatry. [Kowalczyk Mateusz (2026); evidence level 3]
• The co-occurrence of these conditions increases symptom severity, the risk of relapse, and reduces the likelihood of full remission. [Kowalczyk Mateusz (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For l-tyrosine mood randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Milkarizi Narges (2026). Effects of Hydro‐Ethanolic Extract of Portulaca oleracea (Purslane) on Depression, Anxiety, and Stress Symptoms in Patients With Non‐Alcoholic Fatty Liver Disease: A Randomized Double‐Blind Controlled Trial. DOI: 10.1002/hsr2.72681. PMCID: PMC13281410. PMID: 42327473. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13281410/
• Kowalczyk Mateusz (2026). Amino Acid–Fatty Acid Profile as a Novel Predictive Method in the Assessment of Diagnosis and Treatment Efficacy of Anxiety-Related Disorders and Mood Disorders. DOI: 10.3390/ijms27114705. PMCID: PMC13256806. PMID: 42278236. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13256806/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.